Dramatic response of metaplastic breast cancer to chemo-immunotherapy

Dramatic response of metaplastic breast cancer to chemo-immunotherapy

Abstract Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a...

Full description

Bibliographic Details
Main Author: Sylvia Adams
Format: Article
Language:English
Published: Nature Publishing Group 2017-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-017-0011-0
id doaj-f7d023da910243e7ba102aee3fa471ff
record_format Article
spelling doaj-f7d023da910243e7ba102aee3fa471ff2020-12-07T18:44:04ZengNature Publishing Groupnpj Breast Cancer2374-46772017-03-01311410.1038/s41523-017-0011-0Dramatic response of metaplastic breast cancer to chemo-immunotherapySylvia Adams0New York University School of Medicine, Perlmutter Cancer CenterAbstract Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.https://doi.org/10.1038/s41523-017-0011-0
collection DOAJ
language English
format Article
sources DOAJ
author Sylvia Adams
spellingShingle Sylvia Adams
Dramatic response of metaplastic breast cancer to chemo-immunotherapy
npj Breast Cancer
author_facet Sylvia Adams
author_sort Sylvia Adams
title Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_short Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_full Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_fullStr Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_full_unstemmed Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_sort dramatic response of metaplastic breast cancer to chemo-immunotherapy
publisher Nature Publishing Group
series npj Breast Cancer
issn 2374-4677
publishDate 2017-03-01
description Abstract Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.
url https://doi.org/10.1038/s41523-017-0011-0
work_keys_str_mv AT sylviaadams dramaticresponseofmetaplasticbreastcancertochemoimmunotherapy
_version_ 1724397411543023616

Similar Items